We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke

By LabMedica International staff writers
Posted on 22 Aug 2024
Print article
Image: The new platelet-centric scoring system predicts platelet hyperreactivity and related risk of cardiovascular events (Photo courtesy of Shutterstock)
Image: The new platelet-centric scoring system predicts platelet hyperreactivity and related risk of cardiovascular events (Photo courtesy of Shutterstock)

Platelets, which are cell fragments circulating in the blood, play a critical role in clot formation to stop bleeding. However, in some individuals, platelets can become "hyperreactive," leading to excessive clotting and causing heart attacks, strokes, and peripheral artery disease, affecting millions worldwide. Until now, assessing platelet reactivity in patients has been challenging due to inconsistencies in the conventional test, platelet aggregometry, which often shows varied results across different laboratories. To overcome this issue, researchers have now accurately identified patients with hyperreactive platelets and conducted a study revealing significant genetic variations among those with hyperreactive platelets compared to others. Using bioinformatics, they developed a new metric called the Platelet Reactivity ExpresSion Score (PRESS), which effectively identifies those at risk of heart attacks and spots those who might not yet know their risk.

Researchers at NYU Grossman School of Medicine (New York, NY, USA) designed PRESS by switching to a low-dose epinephrine aggregometry technique, which is more indicative of hyperreactivity than previous high-dose tests. This method determined hyperreactive platelets based on their reaction to a minimal stimulus. To move beyond the confines of specialized laboratory techniques, the team developed PRESS as a standardizable, genetic-based score to predict cardiovascular risk. This tool was designed to be broadly applicable, avoiding the variability of direct platelet testing.

The researchers validated the clinical relevance of PRESS in a study tracking major adverse cardiovascular events in patients undergoing procedures to clear blocked arteries. Upon comparing PRESS to traditional aggregometry results and examining its diagnostic ability in various patient populations, they found that higher PRESS scores correlated with increased cardiovascular events. The findings, published online on August 20 in Nature Communications, found that those identified as having hyperreactive platelets faced a significantly higher risk of serious cardiovascular events shortly after surgery, providing a new tool for early identification and management of patients at risk due to platelet hyperreactivity.

"Our results demonstrate that our new platelet-centric scoring system can, for the first time and across populations, circumvent aggregometry to reliably predict platelet hyperreactivity and the related risk of cardiovascular events," said corresponding study author Jeffrey Berger, MD, director of the Center for the Prevention of Cardiovascular Disease at NYU Grossman School of Medicine.

"In current practice, anti-platelet therapy is not routinely recommended for the prevention of a first heart attack or stroke, but a platelet-based test would help to identify patients at highest risk, and those who would benefit most from anti-platelet therapy to prevent a cardiovascular event," added study author Tessa Barrett, PhD, assistant professor in the departments of Medicine and Pathology at NYU Langone. "Our score has the potential to further personalize cardiovascular disease risk prevention."

Related Links:
NYU Grossman School of Medicine

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Sekisui Diagnostics UK Ltd.